植入前遗传学检测周期中体外成熟中期I卵母细胞发育的可利用囊胚
本研究比较了植入前遗传学检测(PGT)周期中体外成熟中期I(MI)卵母细胞与体内成熟卵母细胞来源囊胚的可利用囊胚率。共纳入154个PGT周期的1810个注射用中期II(MII)卵母细胞,其中1577个为体内成熟,233个为体外成熟MI卵母细胞。两组可利用囊胚率相似(校正RR 0.97,95%CI 0.40-2.34)。体外成熟MI卵母细胞来源的可利用囊胚已获得3例活产。作者认为,对于可用胚胎少的女性,这些囊胚可考虑为有价值。
要点
- 体外成熟MI卵母细胞与体内成熟卵母细胞来源囊胚的可利用囊胚率相似(校正RR 0.97,95%CI 0.40-2.34)。
- 体外成熟MI卵母细胞来源的可利用囊胚已获得3例活产。
- 作者认为,对于可用胚胎少的女性,这些囊胚可考虑为有价值。
核心结论
- 若体外成熟MI卵母细胞能受精并发育为囊胚,其提供可利用移植胚胎的能力与体内成熟卵母细胞来源的囊胚相似。
- 这些囊胚对于辅助生殖技术周期中可用胚胎少的女性可考虑为有价值。
研究设计与样本
- 研究比较了PGT周期中体外成熟MI卵母细胞与体内成熟卵母细胞来源囊胚的可利用囊胚率。
- 共纳入154个PGT周期的1810个注射用MII卵母细胞,涉及154对夫妇;其中1577个为体内成熟,233个为体外成熟MI卵母细胞。
- 采用广义估计方程的逻辑回归分析控制混杂因素,比较囊胚可利用概率及胚胎学结局。
- 临床与妊娠结局比较采用Student t检验、Mann-Whitney U检验、卡方检验或Fisher精确检验。
主要发现
- 体外成熟MI卵母细胞组与体内成熟卵母细胞组的可利用囊胚率相似(校正RR 0.97,95%CI 0.40-2.34)。
- 使用体外成熟MI卵母细胞来源的可利用囊胚已获得3例活产。
关键数值与推荐
- 可利用囊胚率:体外成熟MI卵母细胞组 vs 体内成熟卵母细胞组,校正RR 0.97(95%CI 0.40-2.34)。
临床怎么用
- 作者认为,对于辅助生殖技术周期中可用胚胎少的女性,体外成熟MI卵母细胞来源的囊胚可考虑为有价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Are blastocysts derived from in-vitro-matured metaphase I (MI) oocytes less likely to produce usable embryos for transfer compared with those derived from in-vivo-matured oocytes in cycles undergoing preimplantation genetic testing (PGT)? DESIGN: The primary outcome was usable blastocyst rate, which was compared between blastocysts derived from in-vitro-matured MI oocytes after ovarian stimulation and from in-vivo-matured oocytes. Logistic regression analysis using generalized estimating equations was used to control for confounders in the analysis of factors that may influence the chance of a blastocyst being usable and in the comparison of embryological outcomes. Student's t-test, Mann-Whitney U test, chi-squared tests or Fisher's exact tests were used to compare clinical and pregnancy outcomes. RESULTS: A total of 1810 injected metaphase II (MII) oocytes from 154 PGT cycles involving 154 couples were included in this study. A total of 1577 MII oocytes were in-vivo-matured and 233 were in-vitro-matured MI oocytes. The usable blastocyst rate was similar between the in-vitro-matured MI oocyte group and the in-vivo-matured oocyte group (adjusted RR 0.97, 95% CI 0.40 to 2.34). Three live births were achieved using usable blastocysts derived from in-vitro-matured MI oocytes. CONCLUSIONS: If in-vitro-matured MI oocytes can be fertilized and develop into blastocysts, their ability to provide usable embryos for transfer is similar compared with those developed from in-vivo-matured oocytes. These blastocysts could be considered valuable for women with few viable embryos in assisted reproductive technology cycles.
引用
- Li Y, Jin L, Tian W, et al. Usable blastocysts developed from in-vitro-matured metaphase I oocytes in preimplantation genetic testing cycles. Reprod Biomed Online. 2023. PMID: 38244346. doi:10.1016/j.rbmo.2023.103571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。